Member Info for The.Italian

re china application as expected,but nice to have it confirmed.

https://www.proactis.com/uk/company/news/2019/may/proactis-gbg-accelerated-payments_facility/ just a reminder from 2019 that we have a relationship with this company.

todays RNS refers to this as the second customer. had a quick look and cannot see RNS for the first although i could have missed. it.very little detail today ,as opposed to the October one, but this may suggest it is a much more substantial and commercially sensitive win (or it may not).anyway good news.

thanks

not entirely sure but aren't the Proactis SA results due tomorrow? happy to be corrected if wrong.

well that is very encouraging besty .thats pretty mainstream. need to maintain perspective but very good news imo.

well spotted albert.i thought i had paid a lot for mine.now i understand why.also its damned heavy to use. more like dragging round an anchor!

my thinking also LF.not all performers are comfortable in these enforced sterile environments and understandably so, but wilson should be fine.plenty of tv experience will help i expect. try "goldzimmerframe.co.uk." excellent service and high quality frames. tad expensive though!

thanks LF.i don't feel so bad now.think the Kaiser chiefs tonight is going to be interesting.i expect them to put on a first rate show and they seem to have been pretty active promoting it. gla

well i was sort of thinking along those lines mel. sorry to say i only recognise the names of 9 on your list and not sure what some of those look like though. dont worry I'm not the target audience! funny to see noddy holder mentioned. i was telling my wife this morning that i saw Slade when they were the N Betweens (i think) performing in a youth club. now work out how old i am. lol

https://www.theguardian.com/music/2020/nov/27/dua-lipa-studio-2054-live-stream-review-perfect-escapist-pop hope this is the right review.

morning bignose.all perfectly tenable views as well and tbh as long as one of us is right and the s/p goes up i don't mind who it is. in fact would prefer it to be you as of course i invested on the basis of fortacin and would like to see it succeed after all these years. i completely agree that longevity as an investment concept may prove to be no more than rich entrepreneurs vanity projects,but i do worry that mellon has lost interest in fortacin as a product. no mention by him so far as I'm aware for a long time.obviously it could all change with fda approval(or the prospect of it and i do expect it to gain approval ultimately) and i do accept the dichotomy between the us and europe which you cite. as always time will tell

morning dougie.as you say there are a number of areas where developments are expected in the medium and short term (also OTC hopefully to start in europe,early 2021, although how this may be impacted by covid and possible production issues is yet to be seen).i doubt if any single one would have the desired effect on the s/p although its possible i suppose that a combination might, but from the fortacin point of view i suspect the jury will remain out for some time.if we are brutally honest the real reason for the current depressed s/p is,imo,the virtual non existent take up of the product.even allowing for undoubted poor marketing and management, if the product was popular we would not be in this position.to what extent the otc switch will improve matters is a complete unknown and i doubt there will be any meaningful news on this front, in terms of sales, for some considerable time. we may have a small spike on news of first sales etc ,but surely any serious investors are going to want to see real substantial numbers before getting on board.the licence agreements re china were pretty muted in their effect so even if we had news in other areas i don't see it as adding another 80% or so. news re the FDA trials should help,but again are investors going to want to see some evidence of sales before committing? .personally i don't see any licence agreement being concluded re us before fda approval,l which is a long way off. i suppose someone might just want to get involved before approval, but if so regent would be negotiating from a position of weakness, so the terms would probably not be good.so for me the more likely trigger fora significant s/p increase is in the longevity area.i expect more acquisitions in this area next yea rend this might engender some significant investor interest in asia.the advantage of the DLI young ai app is that no regulatory approval is required so we are not going to be anguishing over p2/3 trials, although again there must be question marks over how popular such applications will be with consumers and i suspect the real value will lie in the areas of medical research and actuarial and insurance company use, where i suspect there may be very significant opportunities. just my musing and i know there are lots of other ways of looking at things.

LG's tweet going down the river has over 455,000 views now. curtesy of long john silver on twitter.

morning bignose. yes interesting news and thanks again to you and pom. im not much good at US geography but it looks as though its in the same part of the world (state of indiana) as the square one wellness tie in. i suppose its all about building clinical awareness and acceptance. perhaps trying to establish a hub? anyway good news but very very minor i imagine. acorns and oak trees perhaps.i personally don't see it having much impact on the s/p since as you rightly say it comes with significant dilution.could be completely wrong of course and if they continue to bring out announcements it may start to build.

from napster tweeting about the kaiserchiefs 45 mins ago.only to be expected of course, but good to see.

apologies that should read 500,000

i never know whether to attach much weight to these sort of things but for anyone interested during the lunchtime auction someone put 555,000 shares on the bid at 38.5p.it coincided with the small uptick.

60 days it is.

they certainly are.seems likely its Dbay but we may not know for some time as they need 0.87% plus to hit the next reporting threshold, which is actually quite a lot.